
Biopharma company Algernon Pharmaceuticals Inc's (OTC:AGNPF) recently announced plan for a Phase 1 clinical study on DMT for human stroke has just received approval from the Stichting Beoordeling Ethiek Biomedisch Onderzoek (BEBO), an independent Medical Research Ethics Committee.
The trial will be conducted at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands, with screening beginning shortly and dosing expected to start in the fourth quarter of 2022.